Medicine and Dentistry
Prostate Cancer
92%
Transitional Cell Carcinoma
84%
Immune Checkpoint Inhibitor
69%
Overall Survival
53%
Clear Cell Renal Cell Carcinoma
53%
Disease
49%
Urothelial Cancer
42%
COVID-19
34%
Progression Free Survival
31%
Metastatic Carcinoma
30%
Fluorine-18
29%
Positron Emission Tomography
29%
Neoplasm
28%
Clinical Trial
22%
Kidney Metastasis
22%
Immunotherapy
22%
Systematic Review
21%
Hazard Ratio
21%
Cancer
21%
Diagnostic Performance
20%
Mammalian Target of Rapamycin Inhibitor
20%
Radiation Therapy
20%
Androgen Deprivation Therapy
20%
Nivolumab
19%
Cancer Recurrence
19%
Adverse Event
19%
Bladder Cancer
18%
Odds Ratio
18%
Malignant Neoplasm
18%
Cystectomy
17%
Androgen
17%
Cisplatin
16%
Targeted Therapy
15%
Bladder
14%
Bone Metastasis
14%
Programmed Death 1 Ligand 1
14%
Prevalence
13%
Survival Analysis
13%
Cancer Therapy
13%
Meta-Analysis
12%
Solid Malignant Neoplasm
11%
Patient Characteristics
11%
Sunitinib
11%
Everolimus
11%
Durvalumab
11%
Papillary Renal Cell Carcinomas
11%
Quality of Life
11%
Systemic Therapy
11%
Cancer Treatment
10%
Tyrosine-Kinase Inhibitor
10%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Malignant Neoplasm
97%
Transitional Cell Carcinoma
57%
Immune Checkpoint Inhibitor
50%
Disease
49%
Overall Survival
43%
Androgen
40%
Renal Cell Carcinoma
39%
Kidney Metastasis
30%
Progression Free Survival
29%
Metastasis
25%
Neoplasm
23%
Clinical Trial
20%
Mammalian Target of Rapamycin Inhibitor
20%
Fluorine 18
19%
Prevalence
19%
Adverse Event
19%
Bladder Cancer
16%
Apalutamide
15%
Immunotherapy
15%
Castration Resistant Prostate Cancer
14%
Atezolizumab
13%
Sunitinib
12%
Programmed Death 1 Ligand 1
11%
Everolimus
11%
Durvalumab
11%
Solid Malignant Neoplasm
11%
Bone Metastasis
10%
Protein Tyrosine Kinase Inhibitor
10%
Observational Study
9%
Zoledronic Acid
9%
Kidney Carcinoma
9%
Complex II Deficiency
9%
Follitropin Receptor
9%
Placebo
9%
Pathologic Fracture
9%
Case Fatality Rate
9%
Kidney Cancer
9%
5 Hydroxymethylcytosine
9%
Pembrolizumab
9%
Hypertriglyceridemia
9%
Mycobacterium Bovis BCG
9%
Non Muscle Invasive Bladder Cancer
9%
Hyperglycemia
9%
Vasculotropin
9%
Cancer Recurrence
9%
Vaccination Policy
9%
Lenvatinib
9%
Hypercholesterolemia
9%
Gleason Score
8%
Keyphrases
Renal Cell Carcinoma
39%
Urothelial Carcinoma
29%
Advanced Urothelial Cancer
29%
Immune Checkpoint Inhibitors
26%
Overall Survival
20%
Metastatic Renal Cell Carcinoma (mRCC)
19%
Confidence Interval
17%
Histology
14%
Progression-free Survival
13%
Sunitinib
12%
Targeted Therapy
12%
Anticancer Therapy
12%
Non-Hispanic White
11%
Radical Cystectomy
11%
Clinical Trials
11%
Histological Subtypes
11%
Medical Center
10%
Bronx
10%
Initial Treatment
9%
Combined Modality Therapy
9%
Prospective Observational Study
9%
Lower Tract
9%
Synchronous Bone Metastasis
9%
Upper Tract
9%
Telaglenastat
9%
Receptor Activator of nuclear factor-B Ligand
9%
PD-1 Blockade
9%
Apalutamide
9%
Overall Survival Analysis
9%
Threshold Indicator Taxa Analysis (TITAN)
9%
Follicle-stimulating Hormone Receptor
9%
SEER Analysis
9%
Cytoreductive Nephrectomy
9%
Succinate Dehydrogenase Deficiency
9%
Adverse Features
9%
Diverse Populations
9%
Advanced Renal Cell Carcinoma
9%
FSH Receptor
9%
Targeted Cancer Therapy
9%
Multicentre Evaluation
9%
Urothelial Bladder Cancer
9%
Androgen Deprivation Therapy
9%
Personalized Approach
9%
Histological Response
9%
Metabolism-based Therapy
9%
Recurrent Prostate Cancer
9%
SM-88
9%
Racially Diverse
9%
Objective Response Rate
9%
Bacillus Calmette-Guérin
9%